ACRV Acrivon Therapeutics Inc
Price (delayed)
$5.54
Market cap
$172.5M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$2.71
Enterprise value
$132.9M
We are a clinical stage biopharmaceutical company developing precision oncology medicines that we match to patients whose tumors are predicted to be sensitive to each specific medicine by utilizing our
Highlights
Acrivon Therapeutics's debt has decreased by 9% YoY and by 4.9% QoQ
The EPS has plunged by 187% YoY but it has grown by 2.5% from the previous quarter
ACRV's equity is up by 43% YoY but it is down by 9% QoQ
ACRV's net income has dropped by 54% year-on-year and by 12% since the previous quarter
ACRV's quick ratio is down by 21% from the previous quarter and by 17% YoY
Key stats
What are the main financial stats of ACRV
Market
Valuations
Earnings
Shares outstanding
31.14M
Market cap
$172.5M
Enterprise value
$132.9M
Price to earnings (P/E)
N/A
Price to book (P/B)
0.87
Price to sales (P/S)
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Revenue
$0
Gross profit
$0
Operating income
-$85.3M
Net income
-$76.98M
EBIT
-$76.98M
EBITDA
-$75.24M
Free cash flow
-$63.77M
Per share
Balance sheet
Liquidity
EPS
-$2.71
EPS diluted
-$2.71
Free cash flow per share
-$1.67
Book value per share
$6.36
Revenue per share
$0
TBVPS
$5.63
Total assets
$214.68M
Total liabilities
$17.79M
Debt
$4.01M
Equity
$196.89M
Working capital
$174.17M
Debt to equity
0.02
Current ratio
12.75
Quick ratio
12.66
Net debt/EBITDA
0.53
Margins
Efficiency
Dividend
EBITDA margin
N/A
Gross margin
N/A
Net margin
N/A
Operating margin
N/A
Return on assets
-43.7%
Return on equity
-48%
Return on invested capital
-59%
Return on capital employed
-38.5%
Return on sales
N/A
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
ACRV stock price
How has the Acrivon Therapeutics stock price performed over time
Intraday
-5.3%
1 week
2.21%
1 month
-1.95%
1 year
45.79%
YTD
-7.97%
QTD
-7.97%
Financial performance
How have Acrivon Therapeutics's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$85.3M
Net income
-$76.98M
Gross margin
N/A
Net margin
N/A
ACRV's net income has dropped by 54% year-on-year and by 12% since the previous quarter
The operating income has dropped by 52% year-on-year and by 12% since the previous quarter
Growth
What is Acrivon Therapeutics's growth rate over time
Valuation
What is Acrivon Therapeutics stock price valuation
P/E
N/A
P/B
0.87
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
The EPS has plunged by 187% YoY but it has grown by 2.5% from the previous quarter
ACRV's equity is up by 43% YoY but it is down by 9% QoQ
The P/B is 21% below the last 4 quarters average of 1.1
Efficiency
How efficient is Acrivon Therapeutics business performance
The ROIC has plunged by 55% YoY and by 2.1% from the previous quarter
Acrivon Therapeutics's return on equity has decreased by 48% YoY
The ROA has contracted by 45% YoY
Dividends
What is ACRV's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for ACRV.
Financial health
How did Acrivon Therapeutics financials performed over time
The total assets is up by 42% year-on-year but it is down by 7% since the previous quarter
ACRV's total liabilities is up by 37% year-on-year and by 22% since the previous quarter
Acrivon Therapeutics's debt is 98% lower than its equity
ACRV's equity is up by 43% YoY but it is down by 9% QoQ
The debt to equity has declined by 33% year-on-year
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.